Business
Coeptis Therapeutics Holdings, Inc.: We have taken advantage of these reduced reporting burdens herein, and the information that we provide may be different than what you might get from other public companies in which you hold stock.
Revenue was $1.4M, while Net income decreased 11.6% to ($11.9M).
The read at a glance✓ Audited against SEC data
- Earnings — FY2025 net income ($11.9M)Watch
- Profitability — Net income ($11.9M)Watch
- Balance-sheet lens — Credit, capital, funding and liquidityNote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Z Squared Inc. reports it. History and quarterly detail are in the app.
- Sale$1.4M
- Advertising Campaigns$1.3M
- Webinar Services$113K
Leadership changes
From Z Squared Inc.'s own filings, the day they're filed.
- Jeffery Harris · Chief Technology Officer · appointmenteff. 2026-06-24
- Michelle Burke · Chief Executive Officer · departureeff. 2026-05-22
- Ryan Schadel · Chief Marketing Officer · appointmenteff. 2026-04-27
Latest filings
- 8-K · Company announcement2026-08-26
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-07-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Z Squared Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.